Bromelain was first reported to be of value as an analgesic/anti-inflammatory for use in both rheumatoid arthritis and osteoarthritic patients in 1964 (24
). Clinical trials have assessed the effectiveness of bromelain most frequently using preparations containing differing complexes of proteolytic enzymes and differing concentrations of bromelain. Three complexes have been used: (i) PhlogenzymeTM
(PHL), which contains the proteolytic enzymes bromelain (90
mg/tab), trypsin and rutin; (ii) WobenzymeTM
(WOB) which contains bromelain (45
mg/tab), papain, trypsin, chymotrypsin, pancreatin, lipase and amylase; and (iii) Wobenzym NTM
(WOB-N) which contains bromelain (45
mg/tab), trypsin, papain, chymotrypsin, pancreatin and rutin. Bromelain has been assessed in the treatment of osteoarthritis of two joints, i.e. the knee (24
) and the shoulder (as assessed under the global term periarthritis humeroscapularis) (31
). and summarise those studies that have investigated the effect of bromelain in knee and shoulder osteoarthritis, respectively.
Summary of studies assessing the effectiveness of bromelain as a treatment for osteoarthritis of the knee
Summary of studies assessing the effectiveness of bromelain as a treatment for osteoarthritis of the shoulder (periarthritis humero scapularis)
The majority of studies assessing bromelain for osteoarthritis have been either open studies (24
) or equivalence studies designed to assess comparative effectiveness and safety against standard NSAIDs treatment (25
, Klein, 1994, unpublished data.). A number of these studies are unpublished [as reviewed by Leipner et al
)], including two placebo controlled studies designed to assess the efficacy of bromelain in knee osteoarthritis. The following sections will review the studies that have been carried out to date. Direct comparison between these trials is difficult as different dosages or preparations of bromelain have been administered. The majority of the studies have methodological issues that make it difficult to draw definite conclusions.
Bromelain for Knee Osteoarthritis
Ten studies have been identified that have assessed bromelain in osteoarthritis of the knee (). The earliest reported studies investigating bromelain were a series of case reports on 28 patients, with moderate or severe rheumatoid or osteoarthritis, described by Cohen and Goldman (24
). The studies reported indicated that the use of bromelain, at varying doses (these doses were relatively low as compared to subsequent studies) and differing duration, had positive clinical effects in 18 patients (as measured by assessment of reduction in soft tissue swelling, pain and/or joint stiffness) and no adverse events associated with the medication were reported in any of these case reports. This data therefore provided a plausible basis for the further assessment of bromelain in musculoskeletal disorders.
Four unpublished studies: two placebo-controlled, randomised trials and two controlled and randomised studies were reported in the review by Leipner et al
). These studies were designed to assess the comparative effectiveness of bromelain with a standard treatment, the NSAID diclofenac (DF). No significant improvement in outcome was observed in either of the two placebo-controlled trials but both are of poor methodological quality. The outcome measure for one of the unpublished trials may have been inappropriate and both studies may have been inadequately powered (sample size in both studies was n
= 60). In addition, in common with the majority of studies assessing bromelain for this indication, the treatment period was short (3 weeks duration) as compared to normal herbal practice where this preparation may be prescribed for 2–3 months in the first instance. Definitive conclusions cannot therefore be drawn from these two efficacy studies. However the safety and tolerability in both these studies appeared adequate as only minor (mainly gastrointestinal) adverse events were reported and dropout rates were low (5% in both studies). Klein and Kullich's (27
) double blind, randomised, controlled trial of 73 patients with osteoarthritis of the knee compared a commercial proteolytic enzyme preparation (Phlogenzym®) containing bromelain (among other proteolytic enzymes) with a dose of DF (100–150
). They report an equivalent reduction in pain indices of 80% for the two treatments during 3 weeks of therapy and 4 weeks of follow-up with few adverse reactions to either treatment. The two unpublished comparative trials identified that treatment with bromelain (540
mg/day as part of the complexes PHL or WOB) reduced osteoarthritis symptoms and that the reduction was comparable to standard treatment. However, again the treatment period in both these studies was short and it is not possible to identify if the study was adequately powered as no sample size calculations are available. Tolerability was good with both PHL and WOB; however, a high rate of adverse drug reactions (none serious) was reported in the WOB study, with a rate of reporting of 50% of subjects in the WOB and the DF treatment groups. These unpublished reports therefore show equivocal evidence in support of bromelain in osteoarthritis, but highlight the potential safety issue.
Four published studies reported trials to assess the effectiveness of bromelain for knee osteoarthritis (26
). These studies used similar treatment periods (3 or 4 weeks) and similar daily doses of a standard treatment, DF (150–100
mg/day); however, different doses of bromelain were tested (range from 540 to 1890
mg/day). The first study reported by Singer and Oberleitner (26
) assessed bromelain at a dose of 945
mg/day (which is higher than that used in most studies) versus DF after 4 weeks of treatment, and although assessment of equivalence was not reported, both groups showed similar reductions in the primary outcome. However, there were more adverse drug reactions (mainly gastrointestinal: 13 in the WOB group versus nine in the DF group) and drop-outs (20% WOB versus 10% DF) as compared to the standard treatment group, which raises concerns about the safety and tolerability of bromelain at this higher dose. These safety and tolerability issues were not replicated in the study by Tilwe et al
) who administered a daily bromelain dose of 1890
mg/day (in the form of the complex PHL) against the DF comparative group. Equivalence was not tested in this study, but both groups showed reduced symptoms of pain and swelling (comparable across groups), and also joint tenderness (the improvement was significantly better in the PHL group). Tolerability was deemed good (there were no drop-outs), and no significant safety issues were raised in this study despite the high dose employed. The final comparative study was reported by Singer et al
) who compared bromelain (in the complex PHL) at a dose of 540
mg/day against DF in 68 subjects. This study demonstrated that bromelain showed significantly better improvement in both the primary outcome (Lequesne index, P
= 0.017) and summary pain scores (P
= 0.047) as compared to DF. Tolerability and safety were acceptable and levels were similar in both treatment groups. In summary, the four comparative trials indicate that bromelain appears to be as effective as the standard treatment in osteoarthritis of the knee, but higher doses may be associated with safety concerns.
Finally, Walker et al
) recently described an open study of one month treatment intervention of bromelain using two dose regimes (200 and 400
mg) in otherwise healthy adults (n
= 77) with acute knee pain with no medical diagnosis. The data identified a significant clinical improvement compared to baseline in both the primary outcome [symptoms assessed by the Western Ontario McMaster University Arthritis Index, WOMAC (32
)] and in the secondary outcomes (overall psychological wellbeing), at both doses. Furthermore, mean improvements in total symptom score, stiffness and physical function and psychological well-being were significantly greater in the high-dose compared with the low-dose group. However, definitive conclusions cannot be drawn from this study since there are a number of methodological shortcomings. These include the issue of power, which was not addressed: there was no control group (and therefore bias cannot be eliminated) and these patients did not have a formal diagnosis of their knee pain.
In conclusion, bromelain appears to have potential for the treatment of knee osteoarthritis. However it is important to note that there are a number of methodological issues that are common to the studies reported, including the possibility of inadequate power, inadequate treatment periods, inadequate or non-existent follow-up to monitor possible adverse drug reactions. Furthermore, the optimum dosage for this condition remains unclear. A phase II clinical trial would be beneficial to identify the optimal dosage and to systematically monitor safety issues before a definitive efficacy study could be completed.
Bromelain for Osteoarthritis of the Shoulder
Two studies have assessed the use of bromelain in osteoarthritis of the shoulder (31
, Klein, 1994, unpublished data) (). Both studies have assessed the complex PHL, which has been used at the same daily dose (equivalent of 540
mg bromelain per day) and for the same treatment period of 3 weeks with no follow-up. The first study (by Klein, 1994) is an unpublished report of a double blind placebo controlled trial assessing PHL in 60 patients. No significant difference in treatment groups was observed after treatment. The level of adverse drug reactions and rate of drop out was low. However, there are a number of methodological caveats. It is unclear if the study was adequately powered to detect treatment group differences and, as with the knee osteoarthritis studies, the treatment period and lack of follow-up period are inadequate and the optimum dosage is not clear. The second study by Klein et al
) was designed to compare PHL against the standard DF treatment (100
mg/day) in n
= 40 patients with this condition. No group differences in the primary outcome measures (summary pain score) were observed and safety and tolerability were adequate at this dose. However, this study also suffers from possibly being inadequately powered, a brief treatment period and limited follow up.
In conclusion the data from these two studies do not provide support for the effectiveness and safety of bromelain in osteoarthritis of the shoulder; further studies are needed that are adequately powered to identify the optimal dose and optimal treatment period for this condition.
Summary of Clinical Trials Assessing Bromelain for Osteoarthritis
The use of bromelain for the treatment of osteoarthritis looks promising. However, a number of methodological caveats indicate that further studies are warranted, in particular phase II clinical trials to identify the optimum dosage, followed by a definitive randomised placebo-controlled trial to confirm its efficacy in the treatment of osteoarthritis.